期刊文献+

Design,synthesis and antifungal activity of carbazole derivatives 被引量:3

Design,synthesis and antifungal activity of carbazole derivatives
原文传递
导出
摘要 The incidence of invasive fungal infections is increasing rapidly. Clinically available antifungal agents suffer from limited efficacy and severe resistance. There is an urgent need to discover antifungal lead compounds with novel chemical scaffold. On the basis of our previously identified tetrahydrocarbazole antifungal leads, the structure-activity relationship was further explored by modifying the scaffold and the side chains. Several targeted compounds showed potent activity against Candida species. Particularly, compound 13i showed better antifungal activity than the lead compound, which can be used as a good starting point for further optimization. The incidence of invasive fungal infections is increasing rapidly. Clinically available antifungal agents suffer from limited efficacy and severe resistance. There is an urgent need to discover antifungal lead compounds with novel chemical scaffold. On the basis of our previously identified tetrahydrocarbazole antifungal leads, the structure-activity relationship was further explored by modifying the scaffold and the side chains. Several targeted compounds showed potent activity against Candida species. Particularly, compound 13i showed better antifungal activity than the lead compound, which can be used as a good starting point for further optimization.
机构地区 School of Pharmacy
出处 《Chinese Chemical Letters》 SCIE CAS CSCD 2014年第2期229-233,共5页 中国化学快报(英文版)
基金 supported in part by the National Natural Science Foundation of China(No.81222044) the 863 Hi-Tech Program of China(No.2012AA020302) Shanghai Rising-Star Program(No.12QH1402600) Shanghai Municipal Health Bureau(No.XYQ2011038)
关键词 Carbazol Antifungal activity Structure-activity relationship Carbazol Antifungal activity Structure-activity relationship
  • 相关文献

参考文献25

  • 1M.A. Pfaller, D.J. Diekema, Epidemiology of invasive candidiasis: a persistent public health problem, Clin. Microbiol. Rev. 20 (200?) 133-163.
  • 2L. Ostrosky-Zeichner, A. Casadevall, J.N. Galgiani, et al. An insight into the antifungal pipeline: selected new molecules and beyond, Nat. Rev. Drug Discov. 9 (2010) 719-727.
  • 3S.K. Fridkin, W.R. Jarvis, Epidemiology of nosocomial fungal infections, Clin. Microbiol. Rev. 9 (1996)499-511.
  • 4H.A. Gallis, R.H. Drew, W.W. Pickard, Amphotericin B: 30 years of clinical experi- ence, Rev. Infect. Dis. 12 (1990) 308-329.
  • 5D.J. Sheehan, C.A. Hitchcock, C.M. Sibley, Current and emerging azole antifungal agents, Clin. Microbiol. Rev. 12 (1999) 40-79.
  • 6D.W. Denning, Echinocandins: a new class of antifungal, J. Antimicrob. Che- mother. 49 (2002) 889-891.
  • 7I.A. Casalinuovo, P. Di Francesco, E. Garaci, Fluconazole resistance in Candida albicans: a review of mechanisms, Eur. Rev. Med. Pharmacol. Sci. 8 (2004) 69-77.
  • 8C. Sheng, W. Zhang, New lead structures in antifungal drug discovery, Curr. Med. Chem. 18 (2011) 733-766.
  • 9W. Wang, G. Dung, J. Gu, et al. Structure-activity relationships of tetrahydro- carbazole derivatives as antifungal lead compounds, Med. Chem. Commun. 4 (2013) 353-362.
  • 10X. Che, C. Sheng, W. Wang, et al. New azoles with potent antifungal activity: design, synthesis and molecular docking, Eur. J. Med. Chem. 44 (2009) 4218- 4226.

同被引文献6

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部